Literature DB >> 15205565

Hyperhomocyst(e)inemia and elevated soluble vascular cell adhesion molecule-1 concentrations are associated with an increased risk of preeclampsia.

Surab Vadachkoria1, Sixto E Sanchez, Chunfang Qiu, Martin Muy-Rivera, M Rene Malinow, Michelle A Williams.   

Abstract

Hyperhomocyst(e)inemia (HHcy) is a risk factor of endothelial dysfunction and preeclampsia. Soluble vascular cell adhesion molecule-1 (sVCAM-1), a specific marker of endothelial dysfunction, is elevated in preeclampsia. Few have assessed the joint contribution of these biomarkers in predicting preeclampsia. We assessed the extent to which HHcy and elevated sVCAM-1 are independently and jointly associated with preeclampsia. We conducted a case-control analysis of 100 preeclampsia cases and 100 controls to test our study hypothesis. Maternal plasma was collected before labor onset. Total plasma homocysteine (tHcy) was measured using high-performance liquid chromatography with electrochemical detection procedures. Plasma sVCAM-1 was determined using ELISA. Using the distribution of each analyte among controls, elevated tHcy was defined as plasma tHcy >6.6 micromol/l and elevated sVCAM-1 was defined as plasma concentrations >845 ng/ml (i.e., values above the median). Odds ratios (OR) and 95% confidence intervals (CIs) were calculated. Compared with women without elevated tHcy and without elevated sVCAM-1 (the referent group), those with elevated sVCAM-1 alone had a 4.1-fold increased risk of preeclampsia (95% CI 1.2-13.8). The OR for women with elevated tHcy alone was 2.2 (95% CI 0.6-7.9). The OR for women with elevated tHcy and sVCAM-1 was 13.2 (95% CI 4.1-42.2). Elevated tHcy and sVCAM-1 together were strongly associated with an increased risk of preeclampsia. Larger, prospective studies are needed to confirm these findings and to determine the extent to which elevated tHcy and sVCAM-1 together in early pregnancy are predictive of preeclampsia risk. Copyright (c) 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205565     DOI: 10.1159/000079067

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  6 in total

1.  Evidence of endothelial dysfunction in preeclampsia and risk of adverse pregnancy outcome.

Authors:  Robert W Powers; Janet M Catov; Lisa M Bodnar; Marcia J Gallaher; Kristine Y Lain; James M Roberts
Journal:  Reprod Sci       Date:  2008-01-09       Impact factor: 3.060

2.  Maternal erythrocyte omega-3 and omega-6 fatty acids, and plasma lipid concentrations, are associated with habitual dietary fish consumption in early pregnancy.

Authors:  Michelle A Williams; Ihunnaya O Frederick; Chunfang Qiu; Lois J Meryman; Irena B King; Scott W Walsh; Tanya K Sorensen
Journal:  Clin Biochem       Date:  2006-09-30       Impact factor: 3.281

3.  The profiles of soluble adhesion molecules in the "great obstetrical syndromes".

Authors:  Nikolina Docheva; Roberto Romero; Piya Chaemsaithong; Adi L Tarca; Gaurav Bhatti; Percy Pacora; Bogdan Panaitescu; Noppadol Chaiyasit; Tinnakorn Chaiworapongsa; Eli Maymon; Sonia S Hassan; Offer Erez
Journal:  J Matern Fetal Neonatal Med       Date:  2018-02-01

4.  Contribution of dietary intakes of antioxidants to homocysteine-induced low density lipoprotein (LDL) oxidation in atherosclerotic patients.

Authors:  Hongseog Seo; Hyunhee Oh; Hyesoon Park; Miyoung Park; Yangsoo Jang; Myoungsook Lee
Journal:  Yonsei Med J       Date:  2010-07       Impact factor: 2.759

Review 5.  Human trophoblast function during the implantation process.

Authors:  Elsebeth Staun-Ram; Eliezer Shalev
Journal:  Reprod Biol Endocrinol       Date:  2005-10-20       Impact factor: 5.211

6.  Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes.

Authors:  Henry Adekola; Roberto Romero; Piya Chaemsaithong; Steven J Korzeniewski; Zhong Dong; Lami Yeo; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2014-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.